Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc.

United States District Court, D. Massachusetts

March 20, 2018

MOMENTA PHARMACEUTICALS, INC. and SANDOZ INC, Plaintiffs,
v.
AMPHASTAR PHARMACEUTICALS, INC, and INTERNATIONAL MEDICATION SYSTEMS, LTD, Defendants.

          AMPHASTAR PHARMACEUTICALS, INC., and INTERNATIONAL MEDICATION SYSTEMS, LTD. By their attorneys,

          Robert A. Delafield II Douglas Carsten (admitted pro hac vice) Natalie J. Morgan (admittedpro hac vice) Joshua Mack (admitted pro hac vice) Chao Qi (admitted pro hac vice) Alina Litoshyk (admitted pro hac vice) WILSON SONSINI GOODRICH & ROSATI

          Michael S. Sommer (admitted pro hac vice) WILSON SONSINI GOODRICH & ROSATI

          Robert A. Delafield II (admitted pro hac vice) WILSON SONSINI GOODRICH & ROSATI

          Sara Tolbert (admitted pro hac vice) WILSON SONSINI GOODRICH «& ROSATI

          Daryl L. Joseffer (admittedpro hac vice) Sheldon Bradshaw (admitted pro hac vice) KING & SPALDING

          Alan D. Rose (BBO # 427280) Meredith Wilson Doty (BBO # 652220) Antonio Moriello (BBO # 685928) ROSE, CHINITZ & ROSE

          DEFENDANTS' MOTION FOR ENTRY OF FINAL JUDGMENT

         Pursuant to Federal Rule of Civil Procedure 58(d), Defendants Amphastar Pharmaceuticals, Inc., and International Medication Systems, Ltd. (collectively "Amphastar") respectfully request entry of final judgment against Plaintiffs Momenta Pharmaceuticals, Inc. and Sandoz, Inc. (collectively "Momenta").

         I. BACKGROUND

         The jury rendered its verdict in this matter on July 21, 2017 (Dkt. No. 1081). The jury found:

1. Defendants Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. (collectively "Amphastar") infringe claims 6, 15, 16, 53, 54, and 62 (the "Asserted Claims") of U.S. Patent No. 7, 575, 886 ("the '886 patent") for use of the 15-25% procedures and Disaccharide Building Block ("DBB") procedure;
2. Momenta should be awarded $0.00 for lost profits and reasonable royalties due to the infringement;
3. The Asserted Claims of the ' 8 86 patent are not ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.